PURPOSE: To examine the incidence, degree, time course, treatment, and symptoms of lymphedema in breast cancer survivors. METHODS: We conducted a 5-year, population-based prospective study of 631 randomly selected Philadelphia and Delaware County, Pennsylvania female residents with incident breast cancer who were diagnosed from 1999 to 2001. Using a questionnaire previously validated against physical therapists' measurement-based clinical criteria, we assigned a score indicating the degree of lymphedema (none, mild, or moderate/severe) to each month of follow-up based on the respondent's perceived differences in hand/arm size. Standard survival analysis methods permitted maximum use of follow-up. RESULTS: Five-year cumulative incidence of lymphedema was 42 (42%) per 100 women. Among the 238 affected women, lymphedema first occurred within 2 years of diagnosis in 80% and within 3 years in 89%. Among 433 women observed for 3 years, 23% reported no more than mild lymphedema, 12% reported moderate/severe lymphedema, and 2% reported chronically moderate/severe lymphedema. Women with mild lymphedema were more than three times more likely to develop moderate/severe lymphedema than women with no lymphedema. Thirty-seven percent of women with mild lymphedema and 68% with moderate/severe lymphedema received treatment. Increasing proportions of women with increasing degree of lymphedema reported symptoms (eg, jewelry too tight, tired/thick/heavy arm). Symptoms present before the first occurrence of lymphedema were associated with a higher probability of later lymphedema (eg, hazard ratio for jewelry too tight = 7.37; 95% CI, 4.26 to 12.76). CONCLUSION: Lymphedema after breast cancer is common but mostly mild. Subtle differences in self-reported hand/arm size and symptoms can be early signs of progressing lymphedema.
PURPOSE: To examine the incidence, degree, time course, treatment, and symptoms of lymphedema in breast cancer survivors. METHODS: We conducted a 5-year, population-based prospective study of 631 randomly selected Philadelphia and Delaware County, Pennsylvania female residents with incident breast cancer who were diagnosed from 1999 to 2001. Using a questionnaire previously validated against physical therapists' measurement-based clinical criteria, we assigned a score indicating the degree of lymphedema (none, mild, or moderate/severe) to each month of follow-up based on the respondent's perceived differences in hand/arm size. Standard survival analysis methods permitted maximum use of follow-up. RESULTS: Five-year cumulative incidence of lymphedema was 42 (42%) per 100 women. Among the 238 affected women, lymphedema first occurred within 2 years of diagnosis in 80% and within 3 years in 89%. Among 433 women observed for 3 years, 23% reported no more than mild lymphedema, 12% reported moderate/severe lymphedema, and 2% reported chronically moderate/severe lymphedema. Women with mild lymphedema were more than three times more likely to develop moderate/severe lymphedema than women with no lymphedema. Thirty-seven percent of women with mild lymphedema and 68% with moderate/severe lymphedema received treatment. Increasing proportions of women with increasing degree of lymphedema reported symptoms (eg, jewelry too tight, tired/thick/heavy arm). Symptoms present before the first occurrence of lymphedema were associated with a higher probability of later lymphedema (eg, hazard ratio for jewelry too tight = 7.37; 95% CI, 4.26 to 12.76). CONCLUSION:Lymphedema after breast cancer is common but mostly mild. Subtle differences in self-reported hand/arm size and symptoms can be early signs of progressing lymphedema.
Authors: T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg Journal: Breast Cancer Res Treat Date: 2000-12 Impact factor: 4.872
Authors: Anne Fleissig; Lesley J Fallowfield; Carolyn I Langridge; Leigh Johnson; Robert G Newcombe; J Michael Dixon; Mark Kissin; Robert E Mansel Journal: Breast Cancer Res Treat Date: 2005-09-15 Impact factor: 4.872
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Sandra A Norman; A Russell Localio; Michael J Kallan; Anita L Weber; Heather A Simoes Torpey; Sheryl L Potashnik; Linda T Miller; Kevin R Fox; Angela DeMichele; Lawrence J Solin Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-26 Impact factor: 4.254
Authors: Justin C Brown; Andrea L Cheville; Julia C Tchou; Susan R Harris; Kathryn H Schmitz Journal: Support Care Cancer Date: 2013-09-07 Impact factor: 3.603
Authors: Renate M Winkels; Kathleen M Sturgeon; Michael J Kallan; Lorraine T Dean; Zi Zhang; Margaret Evangelisti; Justin C Brown; David B Sarwer; Andrea B Troxel; Crystal Denlinger; Monica Laudermilk; Anna Fornash; Angela DeMichele; Lewis A Chodosh; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2017-07-21 Impact factor: 2.226
Authors: Robin J Bell; Penelope J Robinson; Raychel Barallon; Pamela Fradkin; Max Schwarz; Susan R Davis Journal: Support Care Cancer Date: 2013-02-24 Impact factor: 3.603
Authors: Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-28 Impact factor: 7.038
Authors: Funda Meric-Bernstam; John C Rasmussen; Savitri Krishnamurthy; I-Chih Tan; Banghe Zhu; Jamie L Wagner; Gildy V Babiera; Elizabeth A Mittendorf; Eva M Sevick-Muraca Journal: Biomed Opt Express Date: 2013-12-13 Impact factor: 3.732
Authors: Sharon L Kilbreath; Mi-Joung Lee; Kathryn M Refshauge; Jane M Beith; Leigh C Ward; J M Simpson; D Black Journal: Support Care Cancer Date: 2013-03-15 Impact factor: 3.603